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Abstract
Background: The volume, extent and speed of travel have dramatically increased in the past
decades, providing the potential for an infectious disease to spread through the transportation
network. By collecting information on the suspected place of infection, existing surveillance
systems in industrialized countries may provide timely information for areas of the world without
adequate surveillance currently in place. We present the results of a case study using reported
cases of Shigella dysenteriae serotype 1 (Sd1) in European travellers to detect "events" of Sd1,
related to either epidemic cases or endemic cases in developing countries.
Methods: We identified papers from a Medline search for reported events of Sd1 from 1940 to
2002. We requested data on shigella infections reported to the responsible surveillance entities in
17 European countries. Reports of Sd1 from the published literature were then compared with Sd1
notified cases among European travellers from 1990 to 2002.
Results: Prior to a large epidemic in 1999–2000, no cases of Sd1 had been identified in West
Africa. However, if travellers had been used as an early warning, Sd1 could have been identified in
this region as earlier as 1992.
Conclusion: This project demonstrates that tracking diseases in European travellers could be
used to detect emerging disease in developing countries. This approach should be further tested
with a view to the continuous improvement of national health surveillance systems and existing
European networks, and may play a significant role in aiding the international public health
community to improve infectious disease control.
Background
Emerging or re-emerging infections can be defined as
infections that have newly appeared in a population or
have existed but are rapidly increasing in incidence or geo-
graphic range [1]. The potentially devastating effects of an
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emerging or re-emerging disease are related to its capacity
to spread rapidly and therefore to infect many people.
New diseases have often first emerged in resource poor
countries: HIV infection in central Africa [2,3]; Lassa fever
in west Africa [4]; Ebola virus infection in the Democratic
Republic of Congo (ex Zaire)[5]; Marburg haemorrhagic
fever in Zimbabwe [6]; cholera due to Vibrio cholerae O139
on the Indian subcontinent [7,8]; and meningococcal
meningitis caused by the serogroup W135 in Sahelian
countries [9,10].
While the epidemiological characteristics of these diseases
are very different, a common element of HIV [11], menin-
goccccal infections due to the serogroup W135 [12] and
Marburg haemorrhagic fever [13] is that they were first
detected in western countries. Diagnostic capabilities for
certain pathogens are simply not available in many
resource-poor countries, nor are networks for sharing epi-
demiological information. In those countries, therefore,
the emergence or re-emergence of some pathogens is not
likely to be detected.
Early detection and adequate response are key elements in
controlling emerging diseases, which depend upon rapid
clinical diagnosis and containment in populations and in
the environment [3]. In recent years, many efforts have
been made to reinforce laboratory capacities and epidemi-
ological surveillance in countries with limited medical
and laboratory infrastructures. Despite these measures,
many countries still lack basic laboratory facilities, suffi-
cient financial resources to run expensive laboratory tech-
niques, and adequate means of communication for
surveillance purposes.
It is well known that because people travel more often and
to more places than ever before, the potential for infec-
tious disease transmission has increased. But, from an epi-
demiologic perspective, the increase in travel can also
help to provide insight into infectious disease circulation
in other areas of the world, and perhaps make it possible
to detect new events [14]. By collecting information on
the probable place of infection, existing surveillance sys-
tems in industrialized countries can play an important
role in sharing information. However, at national surveil-
lance level, there is no systematic coordinated system to
take advantage of this epidemiological information. Cur-
rent mechanisms to share health information depend on
the "good will" of each country to provide such informa-
tion to the international health community. We explore
the possibility of using European national reporting data
to inform on the presence and changes in patterns of a
specific disease in a region. The goal of this research is to
quantify, using a case example, the effectiveness of this
"travellers' alert" to detect emerging or re-emerging dis-
eases in countries with limited laboratory facilities.
Methods
Choice of Shigella dysenteriae serotype 1
Shigellosis is endemic in numerous developing countries
and the most important cause of dysentery worldwide. It
has been estimated that shigellosis accounts for at least 80
million cases (99% in developing countries) and 700,000
deaths each year, and causes 5 to 10% of diarrhoeal illness
and 75% of diarrhoeal deaths [15,16]. Among shigellosis
infections, we choose Shigella dysenteriae serotype 1 (Sd1)
infections as a case study because Sd1 presents a unique
opportunity to examine the viability of using travellers as
an early alert for several key reasons. First, man is the only
natural host for s higella species, and therefore no other
vectors or reservoirs need to be considered. Second, shig-
ella  infections in industrialized countries are primarily
due to S. sonnei and less frequently to S. flexneri and not to
Sd1 [17]. Therefore, cases of Sd1 in industrialised coun-
tries will have been infected during travel and not in their
country of residence. Third, unlike laboratories in indus-
trialized countries, laboratories in developing countries
often do not have the capacity to identify Sd1. The causa-
tive pathogen is more likely to be identified in western
travellers when they come home, and have access to com-
prehensive laboratory facilities. Because of the short incu-
bation period (average 1 to 3 days [18]) and severe clinical
symptoms, travellers are likely both to seek medical atten-
tion (or follow up care) in their home country and to
recall the probable place of infection during the course of
their trip. In addition, chronic carriage of shigella is very
uncommon. Finally, Sd1 while reported in many develop-
ing countries, seemed to emerge in West Africa in 1999.
We wanted to test how an early alert based on travellers
could have helped in detecting the emergence of Sd1 in
that particular region of the world at that time.
Data sources
We present a comprehensive spatial and temporal review
of notified Sd1 cases. Assuming that the most common
channel of communication in the scientific community
for sharing information about an emerging or re-emerging
diseases is publication in scientific journals, we performed
a comprehensive literature review. We identified papers
from a Medline search for reported events of Sd1 from
1940 to 2002. Both English and French articles were
included in the review (keywords: shigella, shigellosis, dys-
entery, shigella and dysentery, shigella dysenteriae). We also
search PROMED using the same keywords. We included
reports of laboratory confirmed Sd1 and probable Sd1 for
both endemic and epidemic events.
Next, we submitted a protocol of the study and data form
to the responsible surveillance entities in 17 EuropeanBMC Public Health 2007, 7:8 http://www.biomedcentral.com/1471-2458/7/8
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countries (Austria, Belgium, Denmark, France, Finland,
Germany, Greece, Ireland, Italy, Luxembourg, Nether-
lands, Norway, Portugal, Spain, Sweden, Switzerland, and
the United Kingdom). We used the European list of con-
tacts from the International Surveillance Network for the
Enteric Infections Salmonella and VTEC O157 (EnterNet).
Though this existing network for human gastrointestinal
infections did not specifically aim to collect data on Sd1,
in most cases epidemiologists and microbiologists were
also responsible in their country for surveying shigella
infections. We requested data on the date of diagnosis, the
probable place of infection (PPI) (at the country level),
gender, age (less than 1 year, 1– 5 years, 6–14 years, 15–
64 years, and 65 years and over), and antibiogrammes for
Sd1 cases reported between 1990 and 2002.
Then we compared the temporal and geographic distribu-
tion of cases reported in the literature review to data pro-
vided by national surveillance entities. We compiled a
yearly timeline of Sd1 from 1940 to 2002 by country for
the literature review (we collected the date of the events,
and date of publication) and from 1990 to 2002 for the
travellers comparison.
Results
Sd1 infections reported in the literature
The first confirmed and published Sd1 outbreak occurred
in Somalia in 1963–64 [19], followed by a long reporting
gap in Africa until 1979 (Table 1). During this gap, large
outbreaks occurred in Central America: Guatemala in
1968–69 [20,21]; El Salvador [22], Honduras [22], Mex-
ico in 1969 [23]; and Costa Rica in 1970 [22]. A 1972
manuscript mentioned a large outbreak in Bangladesh,
although Sd1 is reported to be endemic in this region
[24]. The following year (1973), a significant outbreak
occurred in Coral Island in the Bay of Bengal, Bangladesh
[25].
Next, we observed in the literature a new wave of reported
cases in Central Africa starting in 1979 in northeast Dem-
ocratic Republic of Congo (DRC, ex-Zaire) [24,26] and
Rwanda [27], followed by Burundi in 1980 [28], DRC
[24,29,30] and Tanzania in 1981 [31], and Tanzania and
Burundi in 1982 [31,32]. Subsequent events in central-
east Africa were not published until the early 1990s. How-
ever, epidemics were observed in India and Burma in
1984 [33-36], in Thailand in 1986 [37] and in Iran in
1988 [38].
From 1990 to 1995, outbreaks of Sd1 were reported in the
literature in central and eastern Africa. A large wave started
in Zambia in 1990–1991 [39-41] and then spread to cen-
tral, eastern and southern Africa in the following years: in
1992, Zimbabwe [42], Swaziland [43], and Burundi [44];
in 1993, Zimbabwe [45], Mozambique [46], Rwanda
[47], Sudan [48], Sao Tome [49], Uganda [49] and
Burundi [44]; in 1994, South Africa [50-52], Mozambique
[46], Kenya [53], Rwanda [54], Zimbabwe [55] and DRC
[56-59]; in 1995, Kenya [60,61], South Africa [62], Zim-
babwe, Mozambique, and Malawi [55]. In 1997, the last
epidemics in that region were reported in South Africa
[63], Kenya [55], Zimbabwe [64] and Somalia [55].
According to the published literature, no outbreaks of Sd1
strains were reported in West Africa until 1999. Dialo et al
first mentioned Sd1 in Senegal in 1999 [65], though for a
limited number of cases. The first large outbreak reported
in West Africa occurred in Sierra Leone at the end of 1999
[66,67]. Endemic cases and outbreaks have been reported
almost every year in India and Bangladesh from 1990 to
2002 [68-71].
Promed reported "dysentery outbreak" mostly in Russia
and North America. The causal germ of the dysentery
(shigella, ETEC or E. histolitica) was most of the time not
identified, or was not shigella dysenteriae.
Sd1 surveillance of European travellers
Of the 17 countries where the protocol was submitted, we
obtained responses from all but one country (Luxem-
bourg). Seven countries reported either no case of Sd1 or
reported cases but without PPI. A total of 263 cases were
reported for the study period. The PPI was available for
178 (68%) of the cases. In five of these, the PPI was
reported as Africa (unspecified country). The most fre-
quent PPI was Senegal where 37 cases were reported over
the study period (5 family-related outbreaks) and India (n
= 21 cases) where cases were reported in all but 3 years of
the study period. Cases were also frequently reported from
Mali (n = 13), Egypt (n = 12), Djibouti (n = 10), Pakistan
(n = 9), Kenya (n = 8), Cape Verde (n = 9), Bangladesh (n
= 6) Ivory Coast (n = 5) and Democratic Republic of
Congo (n = 5). Other countries of probable place of infec-
tion include: Angola (n = 2), Burkina Faso (n = 2), Leba-
non (n = 2), Mauritania (n = 4), Nepal (n = 2), Nigeria (n
= 3), Rwanda (n = 3), Tanzania (n = 3), the United King-
dom (n = 2), Uganda (n = 2), Uzbekistan (n = 3) and
Zambia (n = 3). There were also multiple countries where
the probable place of infection was reported only once
during the study period: Afghanistan, Brazil, Eritrea,
Ghana, Israel, Madagascar, Mozambique, Sudan, Sweden,
Thailand, Tunisia, Turkey and Uganda.
Evaluation of the travellers early alert (Sd1 surveillance of European 
travellers) versus the literature notification
We explore timeliness between notification of an "Sd1
event" using the travellers alert and the literature. For Asia,
the literature review points out the continuous endemicity
of the diseases other the past 4 decades. For South Amer-
ica, no new Sd1 events were reported in the literature orBMC Public Health 2007, 7:8 http://www.biomedcentral.com/1471-2458/7/8
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through the travellers surveillance since the early 70s.
Here, therefore, we only present data from African coun-
tries, in four regions: West Africa region (figure 1), North
East Africa region (figure 2), Central and East Africa region
(figure 3) and South Africa region, including Madagascar
(figure 4). The median delay between the occurrence of an
event and its publication in a journal was 2 years (range 6
months to 6 years).
The travellers alert detected Sd1 infections in several coun-
tries of West Africa: Mauritania (1992), Mali (1993), Tuni-
sia (1994), Burkina Faso (1995), Ivory Coast (1999),
Cape Verde (2000), Ghana (2001) and Nigeria (2001).
We did not find Sd1 mentioned in the literature in any of
these countries. Only one article mentioned Sd1 out-
breaks in Senegal 7 years after the first case would have
been detected through the early alert tested here.
Table 1: Geographic timeline of events of Sd1 reported in the published literature
Year Country Source
1963 Somalia [19]
1968 Southwest Guatemala [22]
1969 Guatemala [20,21]
Salvador [22]
Honduras [23]
Mexico [23]
1970 Costa Rica [22]
1972 Bangladesh [24]
1973 Coral Island (Bay of Bengal) [25]
1979 Northeast Zaire [24,26]
Rwanda [27]
1980 Burundi [28]
1981 Tanzania [31]
Zaire [32]
1982 Tanzania [31]
Burundi [32]
1984 West Bengal, India [33]
Burma [36]
1986 Thailand [37]
1988 Iran [38]
1990 Zambia [40]
1991 Zambia [39]
1992 Zimbabwe [42]
1992 Swaziland [43]
1992 Burundi [44]
1993 Zimbabwe [45]
Mozambique [46]
Rwanda [47]
Burundi [44]
Sudan [48]
Sao Tome [49]
Uganda [49]
1994 South Africa [50–52]
Mozambique [50]
Kwazulu Natal [51]
Kenya [53]
Rwanda [54]
DRC [57]
Zimbabwe [55]
1995 Kenya [60,61]
South Africa [62]
Zimbabwe, Malawi, Mozambique [55]
1997 South Africa [63]
Kenya, Somalia [55]
1999 Sierra Leone [66,67]
Senegal [65]
2002 Eastern India [71]BMC Public Health 2007, 7:8 http://www.biomedcentral.com/1471-2458/7/8
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In North East Africa, the travellers alert detected Sd1 in
Eritrea, Sudan, Egypt, and Djibouti from 1991 to 2000,
while this information had not yet appeared in the
literature.
In Central, East and South African countries, the travellers
alert reported Sd1 in DRC, Angola and Madagascar while
no published data are available. In Kenya, we picked up
an SD1 event 3 years before a large outbreak was men-
tioned in a publication.
The early alert would have identified the presence of Sd1
in West Africa 7 years (1992) before it was reported during
an epidemic (1999). West African countries were not pre-
pared for the magnitude of the Sd1 outbreaks in 1999 or
for the identification of Sd1 in national laboratories.
Travellers' surveillance coincided with the literature
review when cases were reported in Kenya (1994–1996)
and in 1994 where cases were reported in Rwanda, DRC,
and Mozambique.
Discussion
Using Sd1 as an example, our case study suggests that
using existing surveillance systems of European travellers
made it possible to detect an emerging disease in regions
of the world apparently previously unaffected. Travellers
can therefore serve as valuable sentinels in identifying
Timeliness between EAS and literature notification of Sd1 outbreaks in West African countries Figure 1
Timeliness between EAS and literature notification of Sd1 outbreaks in West African countries.
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new or changing infectious disease problems in areas of
the world where resources may be insufficient to provide
full laboratory identification and characterization of
pathogens.
Using travellers as an early warning aims to create an alert,
rather than function as a surveillance system used to fol-
low trends. By using this information as an alert, even par-
tial data proved to be effective in detecting an usual event,
e.g. diagnosis of Sd1 in West Africa through a travellers
alert, 7 years (1992) before an "official" report. The infor-
mation collected by the early alert would be shared with
the Ministry of Health (MoH) concerned. The WHO
should be a natural channel of communication and could
plan a response strategy with the MoH and other partners
such as NGOs. The WHO is normally in a position to
assess the public health relevance of the findings and
therefore to emphasize to the MoH the need for certain
measures. Training of national reference laboratories,
equipment procurement (i.e. medium transport, labora-
tory equipment), training of clinicians to recognise the
disease and adaptation of the surveillance system could
have been implemented in order to improve the capacity
to detect this particular disease in the region.
Several limitations to this analysis require discussion.
Because of the short incubation period (1–3 days), many
travellers with shigellosis are likely to become ill during
travel. Empiric treatment of traveller's diarrhoea with anti-
microbial agents is common; looking at returned travel-
lers would be likely to miss many shigella infections in
travellers. Because Sd1 is not necessarily a reportable dis-
ease or because the information concerning the probable
place of infection was not communicated, many cases
were not recorded at national surveillance levels. Thus, the
total number of SD1 cases reported and used in this anal-
ysis is limited (e.g. 178 cases over a period of 13 years). In
addition, travel patterns, i.e. numbers of travellers to a
specific region in a definite time period, may affect the
capacity of travellers surveillance to create an alert.
Events of Sd1 reported in the literature may contain tem-
poral and spatial inaccuracies, although on a larger tem-
poral and spatial scale they can be considered sufficiently
robust. Reporting bias in the literature may be due to sev-
eral reasons: the lack of diagnosis capacity of a country
may induce decreased reporting. A highly active research
team being collocated in a particular country, on the other
hand, may stimulate publications that would not exist in
Timeliness between EAS and literature notification of Sd1 outbreaks in North East African countries Figure 2
Timeliness between EAS and literature notification of Sd1 outbreaks in North East African countries.
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another country. Other geopolitical factors might increase
the likelihood of identification and reporting of such
endemic disease (civil war, humanitarian emergencies,
the presence of NGOs). The absence of Sd1 in a particular
country through the travellers surveillance should not be
assumed to be due to its true absence from the country.
Differences in travel patterns may also affect the sensibil-
ity of the alert. The "model" proposed here should be con-
sidered as an additional tool to improve detection of
emerging or re-emerging diseases. Nevertheless, the com-
parison between literature reporting and travellers surveil-
lance is intended to test the efficacy of using European
travellers for detecting emerging or re-emerging events of
public health importance, i.e. large numbers of cases usu-
ally reported in the literature. A clear direction for future
research is to examine other forms of surveillance data
rather than the published literature.
Laboratory methods to confirm isolates as Sd1 reported
here were not standardised in Europe, but were consid-
ered valid by each national reference laboratory.
One strength of using a travellers alert is that an isolated
case report is sufficient to suggest circulation of Sd1 in the
PPI and is independent of the magnitude of the events. A
single event of a new pathogen (emerging or re-emerging)
in a region would be sufficient to create the alert. Another
strength of using travellers as an early alert is that denom-
inator information (i.e. total number of travellers to a par-
ticular country or region), which is often difficult to
collect, is not required. This factor is essential compared to
surveillance systems, as in the "model" developed here; in
principle, a single event is sufficient to create the alert.
In this study, only 4 countries had reported resistance pat-
terns of Sd1 identified in travellers (data not shown).
National surveillance systems were not systematically col-
lecting these data, but from 2000, several countries started
to record this information. In the future, recording resist-
ance patterns of Sd1 in travellers could be a useful tool.
However, information of resistance pattern evolution
given by this early alert would remain occasional, and
would not provide a representative sample of the infected
population.
Timeliness between EAS and literature notification of Sd1 outbreaks in Central East African countries Figure 3
Timeliness between EAS and literature notification of Sd1 outbreaks in Central East African countries.
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Through improved data collection (by standardising data
collected and adding information on the probable place
of infection) and international collaboration, the model
used here could be applied to other diseases with short
incubation periods and which are not prevalent in the
travellers' country of origin. Because case counts of such
events are expected to be low, coordination among
national surveillance systems is crucial and probably fea-
sible within the context of institutions covering large pop-
ulations such as the new European Centre for Disease
Prevention and Control (ECDC), the US Centres for Dis-
ease Control (CDC Atlanta) and of course the World
Health Organisation. Travel medical clinic surveillance
systems, such as TropNetEurop [72] or Geosentinel [73]
are used to detect morbidity in travelers and to facilitate
their accurate diagnoses and treatment. They have also
attempted to use their data with the same objective and
should be associated with this network.
Linking databases across countries increases the probabil-
ity of picking up uncommon events. Communication
channels should be developed to relay routinely captured
information to countries and institutions that can use it.
Conclusion
Sentinel surveillance information may be most useful for
infections that can be prevented (e.g., vaccine or other
public health intervention) or treated with effective drugs
(in this instance, information about resistance patterns
may be valuable). Information about resistance patterns
can have potential practical implications both for the res-
idents in the country of origin (of the pathogen) and for
travellers.
This approach should be further tested with a view to the
continuous improvement of national health surveillance
systems and existing European networks, and may play a
significant role in aiding the international public health
community to improve infectious disease control. The
WHO or other international partners could provide the
necessary information to the ministries of health con-
cerned in order to improve laboratory capacity, and train
laboratory personnel and clinicians to diagnose emerging
or re-emerging diseases.
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